126 related articles for article (PubMed ID: 18304653)
1. Should accessory proteins be structural components of lentiviral vaccines? Lessons learned from the accessory ORF-A protein of FIV.
Pistello M
Vet Immunol Immunopathol; 2008 May; 123(1-2):144-9. PubMed ID: 18304653
[TBL] [Abstract][Full Text] [Related]
2. AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens.
Pistello M; Bonci F; Flynn JN; Mazzetti P; Isola P; Zabogli E; Camerini V; Matteucci D; Freer G; Pelosi P; Bendinelli M
J Virol; 2006 Sep; 80(18):8856-68. PubMed ID: 16940498
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of vaccination strategies against infection with feline immunodeficiency virus (FIV) based on recombinant viral vectors expressing FIV Rev and OrfA.
Huisman W; Schrauwen EJ; Tijhaar E; Süzer Y; Pas SD; van Amerongen G; Sutter G; Rimmelzwaan GF; Osterhaus AD
Vet Immunol Immunopathol; 2008 Dec; 126(3-4):332-8. PubMed ID: 18952300
[TBL] [Abstract][Full Text] [Related]
4. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA.
Lockridge KM; Chien M; Dean GA; Stefano Cole K; Montelaro RC; Luciw PA; Sparger EE
Virology; 2000 Jul; 273(1):67-79. PubMed ID: 10891409
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats.
Huisman W; Schrauwen EJ; Pas SD; van Amerongen G; Rimmelzwaan GF; Osterhaus AD
Vaccine; 2008 May; 26(21):2553-61. PubMed ID: 18430494
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of feline immunodeficiency virus ORF-A mutants as candidate attenuated vaccine.
Pistello M; Bonci F; Isola P; Mazzetti P; Merico A; Zaccaro L; Matteucci D; Bendinelli M
Virology; 2005 Feb; 332(2):676-90. PubMed ID: 15680433
[TBL] [Abstract][Full Text] [Related]
7. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
[TBL] [Abstract][Full Text] [Related]
8. Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus.
Dunham SP; Bruce J; Klein D; Flynn JN; Golder MC; MacDonald S; Jarrett O; Neil JC
Vaccine; 2006 Nov; 24(49-50):7095-108. PubMed ID: 17049683
[TBL] [Abstract][Full Text] [Related]
9. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
[TBL] [Abstract][Full Text] [Related]
10. MHC-restricted protection of cats against FIV infection by adoptive transfer of immune cells from FIV-vaccinated donors.
Pu R; Omori M; Okada S; Rine SL; Lewis BA; Lipton E; Yamamoto JK
Cell Immunol; 1999 Nov; 198(1):30-43. PubMed ID: 10612649
[TBL] [Abstract][Full Text] [Related]
11. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats.
Kusuhara H; Hohdatsu T; Okumura M; Sato K; Suzuki Y; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H
Vet Microbiol; 2005 Jul; 108(3-4):155-65. PubMed ID: 15899558
[TBL] [Abstract][Full Text] [Related]
12. Lessons from the cat: development of vaccines against lentiviruses.
Dunham SP
Vet Immunol Immunopathol; 2006 Jul; 112(1-2):67-77. PubMed ID: 16678276
[TBL] [Abstract][Full Text] [Related]
13. Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS.
Klonjkowski B; Klein D; Galea S; Gavard F; Monteil M; Duarte L; Fournier A; Sayon S; Górna K; Ertl R; Cordonnier N; Sonigo P; Eloit M; Richardson J
Vaccine; 2009 Feb; 27(6):928-39. PubMed ID: 19070641
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.
Gupta S; Leutenegger CM; Dean GA; Steckbeck JD; Cole KS; Sparger EE
J Virol; 2007 Jan; 81(2):465-73. PubMed ID: 17079309
[TBL] [Abstract][Full Text] [Related]
15. Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate.
Pu R; Coleman J; Coisman J; Sato E; Tanabe T; Arai M; Yamamoto JK
J Feline Med Surg; 2005 Feb; 7(1):65-70. PubMed ID: 15686976
[TBL] [Abstract][Full Text] [Related]
16. Exogenous glucocorticoids alter parameters of early feline immunodeficiency virus infection.
Barr MC; Huitron-Resendiz S; Selway DR; Henriksen SJ; Phillips TR
J Infect Dis; 2000 Feb; 181(2):576-86. PubMed ID: 10669341
[TBL] [Abstract][Full Text] [Related]
17. Toward a detailed characterization of feline immunodeficiency virus-specific T cell immune responses and mediated immune disorders.
Paillot R; Richard S; Bloas F; Piras F; Poulet H; Brunet S; Andreoni C; Juillard V
Vet Immunol Immunopathol; 2005 Jun; 106(1-2):1-14. PubMed ID: 15910988
[TBL] [Abstract][Full Text] [Related]
18. Mutations in feline immunodeficiency (FIV) virus envelope gene V3-V5 regions in FIV-infected cats.
Motokawa K; Hohdatsu T; Imori A; Arai S; Koyama H
Vet Microbiol; 2005 Mar; 106(1-2):33-40. PubMed ID: 15737471
[TBL] [Abstract][Full Text] [Related]
19. Mucosal infection and vaccination against feline immunodeficiency virus.
Stokes CR; Finerty S; Gruffydd-Jones TJ; Sturgess CP; Harbour DA
J Biotechnol; 1999 Aug; 73(2-3):213-21. PubMed ID: 10486930
[TBL] [Abstract][Full Text] [Related]
20. Sequence variation of the feline immunodeficiency virus genome and its clinical relevance.
Stickney AL; Dunowska M; Cave NJ
Vet Rec; 2013 Jun; 172(23):607-14. PubMed ID: 23749359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
